Dr Cassandra Vandenberg
Honorary (Fellow)
Department of Medical Biology (WEHI)
51 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
DOI: 10.1186/s13046-025-03629-82026
Journal article
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial
DOI: 10.1038/s41416-026-03535-62024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12024
Research grants (other domestic)
Preclinical Validation of New Therapeutics for Low-Grade Serous Ovarian Cancer
2018
Journal article
DNA repair processes are critical mediators of p53-dependent tumor suppression letter
DOI: 10.1038/s41591-018-0043-52012
Journal article
Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells
DOI: 10.1182/blood-2011-12-4009292008
Journal article
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
DOI: 10.1073/pnas.0809957105
RECENT SCHOLARLY WORKS
2025
Journal article
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial
DOI: 10.1038/s41467-025-64130-62025
Journal article
The antibody–drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models
DOI: 10.1177/175883592513324712024
Journal article
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer
DOI: 10.1016/j.isci.2024.1099782024
Journal article
A risk-reward examination of sample multiplexing reagents for single cell RNA-Seq
DOI: 10.1016/j.ygeno.2024.1107932023
Journal article
Targeting homologous recombination deficiency in uterine leiomyosarcoma
DOI: 10.1186/s13046-023-02687-02023
Journal article
Interferon-ε is a tumour suppressor and restricts ovarian cancer
DOI: 10.1038/s41586-023-06421-w2023
Journal article
MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis
DOI: 10.1038/s41418-023-01119-y